Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jan 12, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients.

Some background

Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line treatment for MCL. However, most patients relapse after treatment and need alternative therapies. AlloSCT is commonly used for patients with MCL who relapse after first-line therapy. AlloSCT involves replacing the patient’s cancer cells with healthy stem cells from a donor. Chemotherapy called a conditioning regimen is given first to get rid of any remaining cancer cells. Reduced-intensity regimens have been associated with fewer side effects and improved survival.

The effectiveness of reduced-intensity chemotherapy plus alloSCT as a front-line treatment in patients with MCL remains under investigation.

Methods & findings

This study involved 25 patients with MCL. All patients received reduced-intensity chemotherapy before undergoing alloSCT. Patients were followed-up for an average of 60.5 months.

At the time of alloSCT, 44% of patients had complete disappearance of all signs of cancer. 56% of patients had tumor shrinkage. 

At follow-up, the average progression-free survival (time from treatment until tumor growth or spread; PFS) was 68.8 months. At 2 years, 68% of patients were alive without disease progression. At 5 years, this rate was 56%. Two-year overall survival (patients still alive 2 years later) was 80%. At 5 years, this rate was 75.8%. At 2 years, 21% of patients had experienced relapse.

Severe or life-threatening side effects were reported. The most common of these included infections (50%) and mouth sores or painful gums (25%). 38% of patients experienced mild to moderate graft-versus-host disease (the donated stem cells attack the patient’s healthy cells; GVHD). 58% of patients experienced long-lasting GVHD.

The bottom line

This study concluded that front-line alloSCT is effective for patients with MCL. The authors suggest that this treatment should only be considered for patients with a high risk of disease progression after conventional therapy.

The fine print

The patient population in this study was small. Larger studies and with a comparison group are needed to confirm these results.

Published By :

British Journal of Haematology

Date :

Dec 17, 2018

Original Title :

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

click here to get personalized updates